{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:31:17Z","timestamp":1794328277269,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972773"],"award-info":[{"award-number":["81972773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["20200216"],"award-info":[{"award-number":["20200216"]}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"crossref","award":["JCYJ20190809103203711"],"award-info":[{"award-number":["JCYJ20190809103203711"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changsha Municipal Natural Science Foundation","award":["kq2014211"],"award-info":[{"award-number":["kq2014211"]}]},{"name":"Postgraduate Scientific Research Innovation Project of Hunan Province","award":["No. CX20200259"],"award-info":[{"award-number":["No. CX20200259"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RNA methylation modifications, especially m6A mRNA modification, are known to be extensively involved in tumor development. However, the relationship between N3-methylcytidine (m3C) related genes and tumorigenesis has rarely been studied. In this research, we found that m3C-related genes were expressed at different levels and affected patients\u2019 prognosis across multiple cancer types from The Cancer Genome Atlas and multi-omics levels. Importantly, methyltransferase-like proteins 2A (METTL2A) had a high amplification frequency (~\u20097%) in patients with breast invasive carcinoma (BRCA), and its overexpression was an independent predictor of poor overall survival. Enrichment analysis of associated genes revealed that METTL2A may activate DNA synthesis and cell proliferation pathways in BRCA cells. Through drug sensitivity analysis, Trifluridine, PD407824, and Taselisib were shown to be effective drugs for METTL2A-positive BRCA patients. Overall, our research conducts a holistic view of the expression level and prognostic signature of m3C-related genes with multiple malignancies. Importantly, METTL2A has been intensely explored as a potential oncogene in BRCA, to aid the development of potential drug agents for precision therapy in breast cancer patients.<\/jats:p>","DOI":"10.1186\/s12967-022-03683-2","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:02:48Z","timestamp":1666260168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast Cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3758-8165","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"3683_CR1","doi-asserted-by":"publisher","first-page":"D303","DOI":"10.1093\/nar\/gkx1030","volume":"46","author":"P Boccaletto","year":"2018","unstructured":"Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, de Crecy-Lagard V, Ross R, Limbach PA, Kotter A, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46:D303\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270\u201388.","journal-title":"Cancer Cell"},{"key":"3683_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.gpb.2018.03.003","volume":"16","author":"C Zhang","year":"2018","unstructured":"Zhang C, Jia G. Reversible RNA Modification N1-methyladenosine (m1A) in mRNA and tRNA. Genomics Proteomics Bioinformatics. 2018;16:155\u201361.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"3683_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","volume":"20","author":"P Nombela","year":"2021","unstructured":"Nombela P, Miguel-Lopez B, Blanco S. The role of m6A, m5C and Psi RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20:18.","journal-title":"Mol Cancer"},{"key":"3683_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0006-291X(63)90105-0","volume":"12","author":"RH Hall","year":"1963","unstructured":"Hall RH. Isolation of 3-methyluridine and 3-methylcytidine from solubleribonucleic acid. Biochem Biophys Res Commun. 1963;12:361\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"3683_CR6","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1261\/rna.056259.116","volume":"22","author":"AG Arimbasseri","year":"2016","unstructured":"Arimbasseri AG, Iben J, Wei FY, Rijal K, Tomizawa K, Hafner M, Maraia RJ. Evolving specificity of tRNA 3-methyl-cytidine-32 (m3C32) modification: a subset of tRNAsSer requires N6-isopentenylation of A37. RNA. 2016;22:1400\u201310.","journal-title":"RNA"},{"key":"3683_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1261\/rna.059667.116","volume":"23","author":"L Han","year":"2017","unstructured":"Han L, Marcus E, D\u2019Silva S, Phizicky EM. S-cerevisiae Trm140 has two recognition modes for 3-methylcytidine modification of the anticodon loop of tRNA substrates. RNA. 2017;23:406\u201319.","journal-title":"RNA"},{"key":"3683_CR8","doi-asserted-by":"publisher","first-page":"14695","DOI":"10.1074\/jbc.M117.798298","volume":"292","author":"L Xu","year":"2017","unstructured":"Xu L, Liu X, Sheng N, Oo KS, Liang J, Chionh YH, Xu J, Ye F, Gao YG, Dedon PC, Fu XY. Three distinct 3-methylcytidine (m3C) methyltransferases modify tRNA and mRNA in mice and humans. J Biol Chem. 2017;292:14695\u2013703.","journal-title":"J Biol Chem"},{"key":"3683_CR9","doi-asserted-by":"publisher","first-page":"8309","DOI":"10.1093\/nar\/gkab603","volume":"49","author":"XL Mao","year":"2021","unstructured":"Mao XL, Li ZH, Huang MH, Wang JT, Zhou JB, Li QR, Xu H, Wang XJ, Zhou XL. Mutually exclusive substrate selection strategy by human m3C RNA transferases METTL2A and METTL6. Nucleic Acids Res. 2021;49:8309\u201323.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.10.018","author":"E Sch\u00f6ller","year":"2021","unstructured":"Sch\u00f6ller E, Marks J, Marchand V, Bruckmann A, Powell CA, Reichold M, Mutti CD, Dettmer K, Feederle R, H\u00fcttelmaier S, et al. Balancing of mitochondrial translation through METTL8-mediated m3C modification of mitochondrial tRNAs. Mol Cell. 2021. https:\/\/doi.org\/10.1016\/j.molcel.2021.10.018.","journal-title":"Mol Cell"},{"key":"3683_CR11","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1093\/nar\/gkac184","volume":"50","author":"MH Huang","year":"2022","unstructured":"Huang MH, Peng GX, Mao XL, Wang JT, Zhou JB, Zhang JH, Chen M, Wang ED, Zhou XL. Molecular basis for human mitochondrial tRNA m3C modification by alternatively spliced METTL8. Nucleic Acids Res. 2022;50:4012\u201328.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1133","author":"XL Tan","year":"2011","unstructured":"Tan XL, Moyer AM, Fau-Fridley BL, Fridley BL, Fau-Schaid DJ, Schaid DJ, Fau-Niu N, Niu N, Fau-Batzler AJ, Batzler AJ, Fau-Jenkins GD, Jenkins GD, Fau-Abo RP, Abo RP, Fau-Li L, Li L, Fau-Cunningham JM, Cunningham JM, Fau-Sun Z, et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1133.","journal-title":"Clin Cancer Res"},{"key":"3683_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ng.3073","volume":"46","author":"ML Gatza","year":"2014","unstructured":"Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet. 2014;46:1051\u20139.","journal-title":"Nat Genet"},{"key":"3683_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/em.22456","author":"MA-O Abdel Ghafar","year":"2021","unstructured":"Abdel Ghafar MA-O, El-Rashidy MA, Gharib F, Al-Ashmawy GM. Impact of XRCC1 genetic variants on its tissue expression and breast cancer risk: a case-control study. Environ Mol Mutagen. 2021. https:\/\/doi.org\/10.1002\/em.22456.","journal-title":"Environ Mol Mutagen"},{"key":"3683_CR15","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1126\/sciadv.aaz4551","volume":"6","author":"VV Ignatova","year":"2020","unstructured":"Ignatova VV, Kaiser S, Ho JSY, Bing XY, Stolz P, Tan YX, Lee CL, Gay FPH, Lastres PR, Gerlini R, et al. METTL6 is a tRNA m3C methyltransferase that regulates pluripotency and tumor cell growth. Sci Adv. 2020;6:4551.","journal-title":"Sci Adv"},{"key":"3683_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001744","author":"MA-O Abdel Ghafar","year":"2021","unstructured":"Abdel Ghafar MA-O, Elkhouly RA, Elnaggar MH, Mabrouk MM, Darwish SA, Younis RL, Elkholy RA-O. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med. 2021. https:\/\/doi.org\/10.1136\/jim-2020-001744.","journal-title":"J Investig Med"},{"key":"3683_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115432","author":"SA Lee","year":"2021","unstructured":"Lee SA, Lee KA-O, Kim H, Cho JA-O. METTL8 mRNA methyltransferase enhances cancer cell migration via direct binding to ARID1A. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115432.","journal-title":"Int J Mol Sci"},{"key":"3683_CR18","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.isci.2020.100968","volume":"23","author":"LH Zhang","year":"2020","unstructured":"Zhang LH, Zhang XY, Hu T, Chen XY, Li JJ, Raida M, Sun N, Luo Y, Gao X. The SUMOylated METTL8 Induces R-loop and tumorigenesis via m3C. iScience. 2020;23:100968.","journal-title":"iScience"},{"key":"3683_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/bs.acc.2021.09.007","volume":"106","author":"MT Abdel Ghafar","year":"2022","unstructured":"Abdel Ghafar MT, Soliman NA. Metadherin (AEG-1\/MTDH\/LYRIC) expression: significance in malignancy and crucial role in colorectal cancer. Adv Clin Chem. 2022;106:235\u201380.","journal-title":"Adv Clin Chem"},{"key":"3683_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"3683_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Fau-Collisson EA, Collisson EA, Fau-Mills GB, Mills GB, Fau-Shaw KRM, Shaw KR, Fau-Ozenberger BA, Ozenberger BA, Fau-Ellrott K, Ellrott K, Fau-Shmulevich I, Shmulevich I, Fau-Sander C, Sander C, Fau-Stuart JM, Stuart JM. The Cancer genome atlas pan-cancer analysis project. Nat Genet. 2013. https:\/\/doi.org\/10.1038\/ng.2764.","journal-title":"Nat Genet"},{"key":"3683_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa892","author":"EW Sayers","year":"2021","unstructured":"Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, Comeau DC, Funk K, Kim S, Klimke W, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2021. https:\/\/doi.org\/10.1093\/nar\/gkaa892.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR23","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"JJ Gao","year":"2013","unstructured":"Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"3683_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3683_CR26","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1093\/bioinformatics\/bty1049","volume":"35","author":"H Nguyen","year":"2019","unstructured":"Nguyen H, Shrestha S, Draghici S, Nguyen T. PINSPlus: a tool for tumor subtype discovery in integrated genomic data. Bioinformatics. 2019;35:2843\u20136.","journal-title":"Bioinformatics"},{"key":"3683_CR27","doi-asserted-by":"publisher","first-page":"725133","DOI":"10.3389\/fonc.2021.725133","volume":"11","author":"H Nguyen","year":"2021","unstructured":"Nguyen H, Tran D, Tran B, Roy M, Cassell A, Dascalu S, Draghici S, Nguyen T. SMRT: randomized data transformation for cancer subtyping and big data analysis. Front Oncol. 2021;11:725133.","journal-title":"Front Oncol"},{"key":"3683_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ng.556","volume":"42","author":"A Alimonti","year":"2010","unstructured":"Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42:454\u20138.","journal-title":"Nat Genet"},{"key":"3683_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2006.01.013","volume":"9","author":"AL Richardson","year":"2006","unstructured":"Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121\u201332.","journal-title":"Cancer Cell"},{"key":"3683_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1741-7015-4-16","volume":"4","author":"P Hall","year":"2006","unstructured":"Hall P, Ploner A, Bjohle J, Huang F, Lin CY, Liu ET, Miller LD, Nordgren H, Pawitan Y, Shaw P, et al. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006;4:16.","journal-title":"BMC Med"},{"key":"3683_CR31","doi-asserted-by":"publisher","first-page":"R953","DOI":"10.1186\/bcr1325","volume":"7","author":"Y Pawitan","year":"2005","unstructured":"Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953-964.","journal-title":"Breast Cancer Res"},{"key":"3683_CR32","doi-asserted-by":"publisher","first-page":"10292","DOI":"10.1158\/0008-5472.CAN-05-4414","volume":"66","author":"AV Ivshina","year":"2006","unstructured":"Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66:10292\u2013301.","journal-title":"Cancer Res"},{"key":"3683_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1522","author":"S Loi","year":"2007","unstructured":"Loi S, Haibe-Kains B, Fau-Desmedt C, Desmedt C, Fau-Lallemand F, Lallemand F, Fau-Tutt AM, Tutt AM, Fau-Gillet C, Gillet C, Fau-Ellis P, Ellis P, Fau-Harris A, Harris A, Fau-Bergh J, Bergh J, Fau-Foekens JA, Foekens JA, Fau-Klijn JGM, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007. https:\/\/doi.org\/10.1200\/JCO.2006.07.1522.","journal-title":"J Clin Oncol"},{"key":"3683_CR34","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41:D991\u20135.","journal-title":"Nucleic Acids Res"},{"key":"3683_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649\u201358.","journal-title":"Neoplasia"},{"key":"3683_CR36","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-019-13528-0","volume":"10","author":"FJ Chen","year":"2019","unstructured":"Chen FJ, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10:5679.","journal-title":"Nat Commun"},{"key":"3683_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"GC Yu","year":"2012","unstructured":"Yu GC, Wang LG, Han YY, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Om J Integr Biol. 2012;16:284\u20137.","journal-title":"Om J Integr Biol"},{"key":"3683_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100270","author":"R Bordonaro","year":"2021","unstructured":"Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, P\u00e1pai Z, Prager G, Stein A, Andr\u00e9 T, et al. Trifluridine\/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose\u2013expansion, phase I study. ESMO Open. 2021. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100270.","journal-title":"ESMO Open"},{"key":"3683_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ygyno.2010.05.006","volume":"118","author":"S Arora","year":"2010","unstructured":"Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, Azorsa DO. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol. 2010;118:220\u20137.","journal-title":"Gynecol Oncol"},{"key":"3683_CR40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0072","author":"KW Song","year":"2022","unstructured":"Song KW, Edgar KA, Hanan EA-O, Hafner MA-O, Oeh J, Merchant M, Sampath D, Nannini MA, Hong R, Phu L, et al. RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (inavolisib) efficacy. Cancer Discov. 2022. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0072.","journal-title":"Cancer Discov"},{"key":"3683_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","volume":"32","author":"S Dent","year":"2021","unstructured":"Dent S, Cortes J, Im YH, Dieras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32:197\u2013207.","journal-title":"Ann Oncol"},{"key":"3683_CR42","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.jtho.2019.05.029","volume":"14","author":"CJ Langer","year":"2019","unstructured":"Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, et al. SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (Taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019;14:1839\u201346.","journal-title":"J Thorac Oncol"},{"key":"3683_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpba.2016.04.030","volume":"126","author":"X Ding","year":"2016","unstructured":"Ding X, Faber K, Shi Y, McKnight J, Dorshorst D, Ware JA, Dean B. Validation and determination of taselisib, a beta-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC\u2013MS\/MS. J Pharm Biomed Anal. 2016;126:117\u201323.","journal-title":"J Pharm Biomed Anal"},{"key":"3683_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2468-1253(20)30396-4","volume":"6","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe A, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, Amagai K, Fujitani K, Ogata K, Watanabe K, et al. Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:209\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3683_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/labmed\/lmab040","volume":"53","author":"EM Habib","year":"2022","unstructured":"Habib EM, Nosiar NA, Eid MA, Taha AM, Sherief DE, Hassan AE, Abdel Ghafar MT. MiR-150 expression in chronic myeloid leukemia: relation to imatinib response. Lab Med. 2022;53:58\u201364.","journal-title":"Lab Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:03:49Z","timestamp":1666260229000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03683-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the medical ethics committee of the First Hospital of Changsha, China. The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"476"}}